Article info
PDFReview
Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events
- Correspondence to Stephanie Lheureux, Medical Oncology & Hematology, Princess Margaret Hospital Cancer Centre, Toronto, ON M5G 2C, Canada; Stephanie.Lheureux{at}uhn.ca
Citation
Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events
Publication history
- Received February 3, 2020
- Revision received February 25, 2020
- Accepted February 27, 2020
- First published April 9, 2020.
Online issue publication
July 06, 2020
Article Versions
- Previous version (6 July 2020).
- Previous version (6 July 2020).
- Previous version (6 July 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© IGCS and ESGO 2020. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, an indication of whether changes were made, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.